NEW YORK (GenomeWeb News) – Pacific Biosciences Chief Scientific Officer Eric Schadt has taken on a new post as leader of a genomics-focused institute at the Mount Sinai School of Medicine in New York City.
Schadt will head the Mount Sinai Institute for Genomics and Multiscale Biology, and he will remain with PacBio as a part-time CSO. He also will run PacBio's Single Molecule Real-time Biology user facility for researchers in the Eastern US, which will be based at Mount Sinai.
The institute is the hub of Mount Sinai's genomics studies, and it collaborates with 13 other institutes at the medical school. Schadt is a founding member of Sage Bionetworks, he was executive scientific director of genetics at Rosetta Inpharmatics, and he was a senior research scientist at Roche Bioscience.
Stacey Sias has left her positions at Celera as Senior VP of business development and strategic planning and as an executive director, the company said in a recent filing with the US Securities and Exchange Commission. Sias previously was VP of licensing at Roche Molecular Systems, she was a molecular biologist at Codon and Genentech, and she is a registered patent agent with the US Patent and Trademark Office.
Cancer Genetics has named Elizabeth Czerepak to be its chief financial officer, the Rutherford, NJ-based company said this week. Czerepak is a founder of Bioptima Advisers, a biotech and pharmaceutical industry consulting firm, she was a managing director at Bear Stearns Health Innoventures, and she worked in business development and finance at Merck, BASF Pharma, and Hoffman-La Roche.
Vermillion has appointed former Nanogen President and COO Bruce Huebner to serve on its board of directors. Huebner currently is a managing director at LynxCom Partners. He previously was president of Osmetech Molecular Diagnostics, president and CEO of TrovaGene, and executive VP and COO of Gen-Probe. Huebner also held sales and marketing positions at Quidel, Hybritech, and Roche Diagnostics.
Cristopher McReynolds has been named vice president of business development at Alverix. He previously was CEO of Satoris. Before that, McReynolds was VP of business development for Affymetrix's molecular diagnostics business unit, and prior to that held the same role at Cepheid.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.